Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 43Waldenstrom Macroglobulinemia 4Recurrence 4Lymphoma, Mantle-Cell 3Lymphoma 3Lymphoma, Follicular 2Leukemia, Myeloid, Acute 2Smoldering Multiple Myeloma 1Sarcoma, Kaposi 1Plasmacytoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Hematologic Diseases 1Graft vs Host Disease 1Genetic Diseases, Inborn 1Congenital Abnormalities 1Carcinoma, Renal Cell 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × ixazomib × Clear all
NCT03590652 2025-10-21

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

University of California, San Diego

Phase 2 Terminated
23 enrolled
Plasma cell

Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡